Background of the antigen
ELAC2 is a zinc phosphodiesterase which displays some tRNA 3' processing endonuclease activity. It is thought to be involved in tRNA maturation, acting by removing a 3' trailer from precursor tRNA. ELAC2 also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. A number of allelic variants have been investigated in hereditary prostate cancer.